## Shen Gao

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4849368/publications.pdf

Version: 2024-02-01

414303 516561 1,366 33 16 32 citations h-index g-index papers 39 39 39 2532 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	Functional exosome-mediated co-delivery of doxorubicin and hydrophobically modified microRNA 159 for triple-negative breast cancer therapy. Journal of Nanobiotechnology, 2019, 17, 93.	4.2	207
2	A33 antibody-functionalized exosomes for targeted delivery of doxorubicin against colorectal cancer. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 1973-1985.	1.7	166
3	Macrophage-cancer hybrid membrane-coated nanoparticles for targeting lung metastasis in breast cancer therapy. Journal of Nanobiotechnology, 2020, 18, 92.	4.2	110
4	Penetration and distribution of PLGA nanoparticles in the human skin treated with microneedles. International Journal of Pharmaceutics, 2010, 402, 205-212.	2.6	93
5	Reducible self-assembling cationic polypeptide-based micelles mediate co-delivery of doxorubicin and microRNA-34a for androgen-independent prostate cancer therapy. Journal of Controlled Release, 2016, 232, 203-214.	4.8	85
6	Co-delivery of autophagy inhibitor ATG7 siRNA and docetaxel for breast cancer treatment. Journal of Controlled Release, 2017, 266, 272-286.	4.8	78
7	Regulating the immunosuppressive tumor microenvironment to enhance breast cancer immunotherapy using pH-responsive hybrid membrane-coated nanoparticles. Journal of Nanobiotechnology, 2021, 19, 58.	4.2	67
8	Aptamer-mediated delivery of docetaxel to prostate cancer through polymeric nanoparticles for enhancement of antitumor efficacy. European Journal of Pharmaceutics and Biopharmaceutics, 2016, 107, 130-141.	2.0	66
9	A novel macrophage-mediated biomimetic delivery system with NIR-triggered release for prostate cancer therapy. Journal of Nanobiotechnology, 2019, 17, 83.	4.2	56
10	Biodegradable Stearylated Peptide with Internal Disulfide Bonds for Efficient Delivery of siRNA In Vitro and In Vivo. Biomacromolecules, 2015, 16, 1119-1130.	2.6	54
11	Dual-Blockade Immune Checkpoint for Breast Cancer Treatment Based on a Tumor-Penetrating Peptide Assembling Nanoparticle. ACS Applied Materials & Samp; Interfaces, 2019, 11, 39513-39524.	4.0	54
12	Mechanisms of enzalutamide resistance in castrationâ€resistant prostate cancer and therapeutic strategies to overcome it. British Journal of Pharmacology, 2021, 178, 239-261.	2.7	53
13	Aptamer-conjugated multi-walled carbon nanotubes as a new targeted ultrasound contrast agent for the diagnosis of prostate cancer. Journal of Nanoparticle Research, 2018, 20, 303.	0.8	43
14	SREBP1 siRNA enhance the docetaxel effect based on a bone-cancer dual-targeting biomimetic nanosystem against bone metastatic castration-resistant prostate cancer. Theranostics, 2020, 10, 1619-1632.	4.6	43
15	Tumour microenvironment-responsive lipoic acid nanoparticles for targeted delivery of docetaxel to lung cancer. Scientific Reports, 2016, 6, 36281.	1.6	30
16	Synergistic effect of reduced polypeptide micelle for co-delivery of doxorubicin and TRAIL against drug-resistance in breast cancer. Oncotarget, 2016, 7, 61832-61844.	0.8	16
17	Peptide T7-modified polypeptide with disulfide bonds for targeted delivery of plasmid DNA for gene therapy of prostate cancer. International Journal of Nanomedicine, 2018, Volume 13, 6913-6927.	3.3	16
18	Codelivery of miR-4638–5p and Docetaxel Based on Redox-Sensitive Polypeptide Micelles as an Improved Strategy for the Treatment of Castration-Resistant Prostate Cancer. Molecular Pharmaceutics, 2019, 16, 437-447.	2.3	14

#	Article	IF	CITATIONS
19	Study on the prostate cancer-targeting mechanism  of aptamer-modified nanoparticles and their potential anticancer effect in vivo. International Journal of Nanomedicine, 2014, 9, 5431.	3.3	13
20	Reduction-responsive cross-linked stearyl peptide for effective delivery of plasmid DNA. International Journal of Nanomedicine, 2015, 10, 3403.	3.3	12
21	Current Status of Gene Therapy for Hepatocellular Carcinoma, with a Focus on Gene Delivery Approaches. Current Gene Therapy, 2015, 15, 120-141.	0.9	12
22	Immunologically modified enzyme-responsive micelles regulate the tumor microenvironment for cancer immunotherapy. Materials Today Bio, 2022, $13$ , $100170$ .	2.6	10
23	Nonionic amphiphilic surfactant conjuncted polyethyleneimine as a new and highly efficient non-viral fene carrier. Macromolecular Research, 2009, 17, 19-25.	1.0	9
24	Reducible chimeric polypeptide consisting of octa-d-arginine and tetra-l-histidine peptides as an efficient gene delivery vector. International Journal of Nanomedicine, 2015, 10, 4669.	3.3	9
25	Modification of degradable nonviral delivery vehicle with a novel bifunctional peptide to enhance transfection <i>in vivo</i> . Nanomedicine, 2018, 13, 9-24.	1.7	8
26	Anti-Cancer Activity Based on the High Docetaxel Loaded Poly(2-Oxazoline)s Micelles. International Journal of Nanomedicine, 2021, Volume 16, 2735-2749.	3.3	8
27	DR5 mAb-conjugated, DTIC-loaded immuno-nanoparticles effectively and specifically kill malignant melanoma cells in vivo. Oncotarget, 2016, 7, 57160-57170.	0.8	7
28	Photothermal therapy enhance the anti-mitochondrial metabolism effect of lonidamine to renal cell carcinoma in homologous-targeted nanosystem. Nanomedicine: Nanotechnology, Biology, and Medicine, 2021, 34, 102370.	1.7	6
29	Prevalence and Associated Factors of Suboptimal Daily Peak Inspiratory Flow and Technique Misuse of Dry Powder Inhalers in Outpatients with Stable Chronic Airway Diseases. International Journal of COPD, 2021, Volume 16, 1913-1924.	0.9	5
30	Surface modification with pluronic P123 enhances transfection efficiency of PAMAM dendrimer. Macromolecular Research, 2012, 20, 162-167.	1.0	4
31	Phase I clinical trial of HCâ€1119 soft capsule in Chinese healthy adult male subjects: Pharmacokinetics and safety of singleâ€dose proportionality and effects of food. Prostate, 2021, , .	1.2	3
32	Pyramid-shaped tips based polymer microneedles for transdermal drug or nanoparticle delivery. , 2007,		2
33	Guideline for the evaluation of prescription appropriateness. Annals of Translational Medicine, 2021, 9, 1352-1352.	0.7	1